FibroBiologics starts clinical trial for diabetic foot ulcer therapy CYWC628, targeting 33M patients worldwide.

FibroBiologics has initiated a clinical trial for CYWC628, a fibroblast-based therapy aimed at treating diabetic foot ulcers (DFUs), a condition affecting over 33 million people globally with limited effective treatments. This milestone marks a shift from development to clinical execution, with patient enrollment starting in Q2 2026 and topline data expected by the end of 2026. The company also continues advancing other programs in multiple sclerosis, psoriasis, and immune function restoration, backed by a strong patent portfolio and sufficient capital to support ongoing trials. This progress reflects FibroBiologics' strategy to address chronic diseases through innovative cell therapies.